Novyra Pharmachem
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Novyra Pharmachem do?
Founded in 1987 as Bansisons Beverages Pvt Ltd, Bansisons Tea Industries Ltd has become a prominent player in the tea industry through expansions into tea plantation and successful partnerships.
Who are the competitors of Novyra Pharmachem?
Novyra Pharmachem major competitors are Retro Green Revolut., Octavius Plantations, Indong Tea Co, Kanco Tea & Inds., Tyroon Tea Company, Diana Tea, Warren Tea. Market Cap of Novyra Pharmachem is ₹7 Crs. While the median market cap of its peers are ₹30 Crs.
Is Novyra Pharmachem financially stable compared to its competitors?
Novyra Pharmachem seems to be less financially stable compared to its competitors. Altman Z score of Novyra Pharmachem is -11.6 and is ranked 8 out of its 8 competitors.
Does Novyra Pharmachem pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Novyra Pharmachem latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Novyra Pharmachem allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Novyra Pharmachem balance sheet?
Novyra Pharmachem balance sheet is weak and might have solvency issues
Is the profitablity of Novyra Pharmachem improving?
No, profit is decreasing. The profit of Novyra Pharmachem is -₹5.37 Crs for TTM, -₹5.37 Crs for Mar 2026 and -₹0.06 Crs for Mar 2025.
Is the debt of Novyra Pharmachem increasing or decreasing?
Yes, The net debt of Novyra Pharmachem is increasing. Latest net debt of Novyra Pharmachem is -₹0.18 Crs as of Mar-26. This is greater than Mar-25 when it was -₹0.27 Crs.
Is Novyra Pharmachem stock expensive?
Novyra Pharmachem is not expensive. Latest PE of Novyra Pharmachem is 0, while 3 year average PE is 96.51. Also latest EV/EBITDA of Novyra Pharmachem is 0.0 while 3yr average is 53.15.
Has the share price of Novyra Pharmachem grown faster than its competition?
Novyra Pharmachem has given better returns compared to its competitors. Novyra Pharmachem has grown at ~94.87% over the last 3yrs while peers have grown at a median rate of -0.75%
Is the promoter bullish about Novyra Pharmachem?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Novyra Pharmachem is 23.15% and last quarter promoter holding is 23.15%.
Are mutual funds buying/selling Novyra Pharmachem?
There is Insufficient data to gauge this.